A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients

Clinical Cancer Research

Volumn 16, Issue 15, 2010, Pages 4046-4056

  Nesslinger, Nancy J ^a   Ng, Alvin ^a   Tsang, Kwong Yok ^d   Ferrara, Theresa ^d   Schlom, Jeffrey ^d   Gulley, James L ^d   Nelson, Brad H ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CLINICAL ARTICLE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; POXVIRUS; PRIORITY JOURNAL; PROSTATE CANCER; SERODIAGNOSIS; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIGENS; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BLOTTING, WESTERN; CANCER VACCINES; COMBINED MODALITY THERAPY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC VECTORS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POXVIRIDAE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY;

EID: 77955097760     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0948     Document Type: Article

References (53)

1. Freedland SJ, Moul JW. Prostate specific antigen recurrence after definitive therapy. J Urol 2007;177:1985-91.
2. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 2000;164:1825-9.
3. Miles AK, Rogers A, Li G, et al. Identification of a novel prostate cancer-associated tumor antigen. Prostate 2007;67:274-87.
4. Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun 2006;6:1.
5. Okada T, Akada M, Fujita T, et al. A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin Cancer Res 2006;12:191-7.
6. Jager D, Karbach J, Pauligk C, et al. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun 2005;5:11.
7. Fossa A, Alsoe L, Crameri R, Funderud S, Gaudernack G, Smeland EB. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 2004;53:431-8. (Pubitemid 38657256)
8. Zhou Y, Toth M, Hamman MS, et al. Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line. Biochem Biophys Res Comm 2002;290: 830-8.
9. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35.
10. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994;30A:1797-803.
11. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R. Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res 2005;25:4435-8.
12. Nesslinger NJ, Sahota RA, Stone B, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007;13:1493-502.
13. Hahn S, Nesslinger NJ, Drapala RJ, et al. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model. Int J Cancer 2009;125: 2871-8.
14. Sharma S, Stolina M, Lin Y, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999;163:5020-8. (Pubitemid 29501270)
15. Barbera-Guillem E, May KF, Jr., Nyhus JK, Nelson MB. Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1999;1:453-60.
16. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007;19:209-16.
17. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6: 24-37. (Pubitemid 43053650)
18. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62.
19. Lechleider RJ, Arlen PM, Tsang KY, et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 2008;14:5284-91.
20. Stone B, Schummer M, Paley PJ, et al. Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer 2003;104:73-84.
21. Nesslinger NJ, Pai HH, Ludgate CM, Nelson BH. Effects of standard treatments on the immune response to prostate cancer. In: Hayat MA, editor. Methods of Cancer Diagnosis, Therapy and Prognosis: General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. New York: Springer; 2009, p. 531-55.
22. Larkin MA, Blackshields G, Brown NP, et al. Clustal W, Clustal X. version 2.0. Bioinformatics 2007;23:2947-8.
23. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53.
24. Lopez MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells. J Clin Oncol 2009;27:945-52.
25. Winter SF, Sekido Y, Minna JD, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst 1993;85:2012-8. (Pubitemid 24000985)
26. Bergquist M, Brattstrom D, Larsson A, et al. p53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res 1998;18:1999-2002.
27. Vogl FD, Frey M, Kreienberg R, Runnebaum IB. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000;83:1338-43.
28. Yamazaki Y, Chiba I, Ishikawa M, et al. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma. Odontology 2008;96:32-7.
29. Bergqvist AS, Bergqvist M, Brattstrom D, et al. Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res 2001;21:4141-5.
30. Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M, Miroglu C. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 2004;11:1070-7. (Pubitemid 40053006)
31. Mack U, Ukena D, Montenarh M, Sybrecht GW. Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 2000;7:669-74.
32. Pallasch CP, Struss AK, Munnia A, et al. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005;117:456-9.
33. Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon α. Int J Cancer 2007;121:2562-6.
34. Xue LJ, Su QS, Yang JH, Lin Y. Autoimmune responses induced by Helicobacter pylori improve the prognosis of gastric carcinoma. Med Hypotheses 2008;70:273-6.
35. Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F. Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 2006;94: 1066-70.
36. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
37. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006;12:3394-401.
38. Urba WJ, Nemunaitis J, Marshall F, et al. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colonys-timulating factor secreting, allogeneic, cellular immunotherapy. J Urol 2008;180:2011-7, discussion 7-8.
39. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113: 975-84.
40. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010;464:302-5.
41. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005;117:574-86.
42. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006;66:7741-7. (Pubitemid 44289234)
43. Bodmer D, Schepens M, Eleveld MJ, Schoenmakers EF, Geurts van Kessel A. Disruption of a novel gene, DIRC3, and expression of DIRC3-1 fusion transcripts in a case of familial renal cell cancer and t(2;3)(q35;q21). Genes Chromosomes Cancer 2003;38:107-16.
44. Tominaga K, Magee DM, Matzuk MM, Pereira-Smith OM. PAM14, a novel MRG- and Rb-associated protein, is not required for development and T-cell function in mice. Mol Cell Biol 2004;24:8366-73.
45. Malin D, Sonnenberg-Riethmacher E, Guseva D, et al. The extracellular-matrix protein matrilin 2 participates in peripheral nerve regeneration. J Cell Sci 2009;122:995-1004.
46. Ricci JE, Munoz-Pinedo C, Fitzgerald P, et al. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 2004;117:773-86.
47. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317-30. (Pubitemid 24091790)
48. Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008;14:665-74.
49. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 2004;172:6692-700. (Pubitemid 38669105)
50. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 2009;15: 7029-35.
51. Slingluff CL, Jr., Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009; 15:7036-44.
52. Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007;178:1515-20.
53. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2009;59:663-74.